Aquestive Therapeutics announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited for Libervant Buccal Film to cover the rest of the world, excluding the United States, Canada, and China. The original licensing agreement with Pharmanovia announced in September 2022 covered the European Union, United Kingdom, Sweden, Switzerland, and Norway, as well as countries in the Middle East and North Africa, MENA. "We are pleased to announce the expansion of our collaboration with Pharmanovia," said Daniel Barber, Chief Executive Officer of Aquestive. "We believe Pharmanovia’s experience and geographic footprint align well with our goal of providing patients throughout the world with access to Libervant. This announcement also aligns with our mission to put the patient at the center of everything we do. We will continue to advocate for patient access, patient choice, and patient empowerment on a global basis."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AQST:
- Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervantâ„¢ (diazepam) Buccal Film to Additional Global Markets
- Aquestive Therapeutics upgraded at Wedbush with cash runway extended
- Aquestive Therapeutics upgraded to Outperform from Neutral at Wedbush
- Aquestive Therapeutics sees FY23 revenue $37M-$41M, consensus $37.83M
- Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives